

ESPERION 1Q20 CONFERENCE CALL

May 6, 2020



SAFE HARBOR

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the clinical development and commercialization plans for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including Esperion's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of expanded indications for their effect on cardiovascular events, and Esperion's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet in the United States and European Union. Any express or implied statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion's brand commercialization plans, or approval of expanded indications, that existing cash resources may be used more quickly than anticipated, the impact of COVID-19 on our business, clinical and commercial supply activities and commercial development plans, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law.

ESPERION | Opening Reflections




We salute all healthcare workers for their incredible commitment



Our overall health and long-term conditions are more in focus than ever before

A group of eight business professionals are seated around a long table in a modern office setting. They are silhouetted against a large window that looks out onto a sunset or sunrise. The sun is low on the horizon, creating a bright, warm glow that fills the room. The professionals are engaged in a meeting, with one person gesturing while speaking. The overall atmosphere is professional and collaborative.

We have Successfully Adapted
We Proudly Deliver Day after Day

A silhouette of a person running is shown against a vibrant sunset sky with orange and blue hues. The runner is in mid-stride, with one leg forward and arms pumping. The sun is low on the horizon, creating a strong backlight effect.

We're Running

NEXLETOL™
(bempedoic acid)
Tablets

U.S. Availability March 30, 2020

Initiated HCP contact on April 20

NEXLIZET™
(bempedoic acid and ezetimibe)
Tablets

U.S. Availability June 4, 2020

1+ Month ahead of schedule!

An aerial photograph of a golf course at sunrise. The scene is misty, with a soft orange and yellow glow from the low sun on the left. Numerous trees are scattered across the green landscape, some with autumn-colored foliage. A small body of water is visible in the lower right. The overall atmosphere is serene and beautiful.

It's a Beautiful Day...

50+% Commercial Coverage

20+% Medicare Part D

Our Medicines are Now Approved in Europe

NILEMDO™

(bempedoic acid) Tablet

Lowered LDL-C Up to 28%*

NUSTENDI™

(bempedoic acid and ezetimibe) Tablet

Lowered LDL-C by a Mean of 38%

**Compared to Placebo, in
4 Pivotal Trials Including Over 3600 Patients*



Refer to our Last Public Call for U.S. NEXLETOL™ & NEXLIZET™ Information

ESPERION®



\$1.5 Billion +

**Collaboration Agreements
Around the World with
Expert Cardiovascular
Companies**



\$900M+

**Milestones Plus
Royalties**

**Largest EU Agreement in
Last Decade**



\$600M+

**Milestones and
Development Costs Plus
Royalties**

Largest Japan Agreement

COMMERCIAL OVERVIEW

Mark Glickman CCO



**Experienced
Team Delivering
Access &
Affordability**

Payor Coverage

**50+% Commercial Coverage
20%+ Medicare Part D Coverage
+ Additional in 2020**

**Preferred brand medicines
Tier 2 and Tier 3**

Healthcare providers

**Simplified Prior Authorizations
Minimized Process**

Patients

**~\$10/Rx Commercial Co-Pay
\$45/Rx Medicare Part D Co-Pay**

Conscientious, Virtual, Customized Launch

Accelerated Digital Asset Development

**Territory Managers Completed Virtual Training
Week of April 13th**

**Full Deploy of Digital Assets and Virtual Sales Team
Week of April 20th**

**Adapted 7-day Blister Pack Sample Program to Allow
for One-Touch On-Line Ordering and Direct
Shipment to HCPs**



Commercial Team Considerations




New “Normal”

Measured approach based on geography and health care provider specialty and circumstances



It's Early

Just beginning to scratch the surface in terms of reaching target healthcare providers



Strong Position


Prepared to assist healthcare providers and their patients in every appropriate way possible

FINANCIAL OVERVIEW

Rick Bartram CFO

FINANCIAL INFORMATION: FULLY FUNDED THROUGH PROFITABILITY

Near-Term Capital Proceeds from Collaboration Agreements



Key Financial Data

FY 2019 Revenue	\$148.4M
FY 2020 Revenue	No Guidance Provided
FY 2020 Milestone Cash Proceeds	> \$235M <ul style="list-style-type: none"> Future capital available upon the completion of an ex-US ROW collaboration (4Q 2020)
FY Op Ex Guidance*	\$335 - \$355M
Anticipated Cash Balance at Dec. 31, 2020	> \$100M
Common Shares Outstanding	Basic 27.5M; Fully Diluted 32.4M

*Excludes \$30M of non-cash stock based compensation expense



Our Shared Future Looks Bright.

Thank You Questions?



Tim Mayleben
CEO & President



Mark Glickman
CCO



Rick Bartram
CFO